Niegisch, Günter
3 papers on CoChatORCID 0000-0001-6929-8691
Most cited papers
- Verified
Tailored immunotherapy approach with nivolumab with or without nivolumab plus ipilimumab as immunotherapeutic boost in patients with metastatic renal cell carcinoma (TITAN-RCC): a multicentre, single-arm, phase 2 trial
Grimm, M.-O., Esteban, E., Barthélémy, P., Schmidinger, M., Busch, J., Valderrama, B. P., Charnley, N., Schmitz, M., Schumacher, U., Leucht, K., et al. (2023) · The Lancet Oncology
Renal cell carcinoma treatmentCancer Immunotherapy and Biomarkers
Cited by 37
- Verified
Histone deacetylase 8 is deregulated in urothelial cancer but not a target for efficient treatment
Lehmann, M., Hoffmann, M. J., Koch, A., Ulrich, S. M., Schulz, W. A., & Niegisch, G. (2014) · Journal of Experimental & Clinical Cancer Research
Histone Deacetylase Inhibitors ResearchBladder and Urothelial Cancer Treatments
Cited by 34
- Verified
Downregulation of Cell Cycle and Checkpoint Genes by Class I HDAC Inhibitors Limits Synergism with G2/M Checkpoint Inhibitor MK-1775 in Bladder Cancer Cells
Hoffmann, M. J., Meneceur, S., Hommel, K., Schulz, W. A., & Niegisch, G. (2021) · Genes
Histone Deacetylase Inhibitors ResearchEpigenetics and DNA Methylation
Cited by 28
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free